Jump to main content
Jump to site search

Issue 2, 2017
Previous Article Next Article

ATM, ATR, CHK1, CHK2 and WEE1 inhibitors in cancer and cancer stem cells

Author affiliations

Abstract

DNA inevitably undergoes a high number of damages throughout the cell cycle. To preserve the integrity of the genome, cells have developed a complex enzymatic machinery aimed at sensing and repairing DNA lesions, pausing the cell cycle to provide more time to repair, or induce apoptosis if damages are too severe. This so-called DNA-damage response (DDR) is yet considered as a major source of resistance to DNA-damaging treatments in oncology. Recently, it has been hypothesized that cancer stem cells (CSC), a sub-population of cancer cells particularly resistant and with tumour-initiating ability, allow tumour re-growth and cancer relapse. Therefore, DDR appears as a relevant target to sensitize cancer cells and cancer stem cells to classical radio- and chemotherapies as well as to overcome resistances. Moreover, the concept of synthetic lethality could be particularly efficiently exploited in DDR. Five kinases play pivotal roles in the DDR: ATM, ATR, CHK1, CHK2 and WEE1. Herein, we review the drugs targeting these proteins and the inhibitors used in the specific case of CSC. We also suggest molecules that may be of interest for preclinical and clinical researchers studying checkpoint inhibition to sensitize cancer and cancer stem cells to DNA-damaging treatments.

Graphical abstract: ATM, ATR, CHK1, CHK2 and WEE1 inhibitors in cancer and cancer stem cells

Back to tab navigation

Article information


Submitted
01 Aug 2016
Accepted
25 Nov 2016
First published
30 Nov 2016

Med. Chem. Commun., 2017,8, 295-319
Article type
Review Article

ATM, ATR, CHK1, CHK2 and WEE1 inhibitors in cancer and cancer stem cells

C. Ronco, A. R. Martin, L. Demange and R. Benhida, Med. Chem. Commun., 2017, 8, 295 DOI: 10.1039/C6MD00439C

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.


Search articles by author

Spotlight

Advertisements